Solubilization and characterization of GABAB receptor binding sites from porcine brain synaptic membranes. 1993

M Facklam, and N G Bowery
Department of Pharmacology, School of Pharmacy, University of London.

1. The characteristics of membrane bound GABAB receptors in pig brain are similar to those in rat brain as judged by in vitro binding experiments and sensitivity to GTP. The rank order of affinity of GABAB receptor ligands was CGP 54626 > GABA approximately (-)-baclofen >> CGP 35348 = CGP 36742 > (+)-baclofen in membranes from both species. 2. For solubilization of GABAB receptors from pig brain, washed membranes were preincubated with 5 mM MgSO4 and subsequently incubated with various detergents. 3-[(3-Cholamidopropyl)dimethyl-ammoniol]-1-propane sulphonate (CHAPS) (0.5%) proved to be the most successful, solubilizing 22.7 +/- 4.7% (mean +/- s.e. mean, n = 6) of GABAB receptors. 3. Binding of [3H]-GABA to GABAB receptors solubilized with 0.5% CHAPS exhibited similar characteristics to the binding at membrane bound receptors since, firstly, the Kd and Bmax values (around 30 nM and 450 fmol mg-1 protein, respectively) were comparable; secondly, stereospecific binding for baclofen was obtained in both forms; thirdly, the affinity for the agonists GABA and (-)-baclofen and the antagonists CGP 35348, CGP 36742 and CGP 54626 were the same; fourthly, comparable sensitivity to Ca2+ (2.5 mM) was observed and finally, a similar sensitivity to GTP was apparent. 4. Saturation experiments performed with the GABAB antagonist, [3H]-CGP 54626, indicated a higher Kd value and a lower Bmax value for solubilized (7.7 +/- 2.6 nM and 1033 +/- 41 fmol mg-1 protein, mean +/- s.e. mean, n = 3) than for membrane bound receptors (1.35 +/- 0.08 nM, 1171 +/- 20 fmol mg-1 protein, n = 3).

UI MeSH Term Description Entries
D001923 Brain Chemistry Changes in the amounts of various chemicals (neurotransmitters, receptors, enzymes, and other metabolites) specific to the area of the central nervous system contained within the head. These are monitored over time, during sensory stimulation, or under different disease states. Chemistry, Brain,Brain Chemistries,Chemistries, Brain
D002793 Cholic Acids The 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholanic acid family of bile acids in man, usually conjugated with glycine or taurine. They act as detergents to solubilize fats for intestinal absorption, are reabsorbed by the small intestine, and are used as cholagogues and choleretics. Cholalic Acids,Acids, Cholalic,Acids, Cholic
D005680 gamma-Aminobutyric Acid The most common inhibitory neurotransmitter in the central nervous system. 4-Aminobutyric Acid,GABA,4-Aminobutanoic Acid,Aminalon,Aminalone,Gammalon,Lithium GABA,gamma-Aminobutyric Acid, Calcium Salt (2:1),gamma-Aminobutyric Acid, Hydrochloride,gamma-Aminobutyric Acid, Monolithium Salt,gamma-Aminobutyric Acid, Monosodium Salt,gamma-Aminobutyric Acid, Zinc Salt (2:1),4 Aminobutanoic Acid,4 Aminobutyric Acid,Acid, Hydrochloride gamma-Aminobutyric,GABA, Lithium,Hydrochloride gamma-Aminobutyric Acid,gamma Aminobutyric Acid,gamma Aminobutyric Acid, Hydrochloride,gamma Aminobutyric Acid, Monolithium Salt,gamma Aminobutyric Acid, Monosodium Salt
D006160 Guanosine Triphosphate Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety. GTP,Triphosphate, Guanosine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013552 Swine Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA). Phacochoerus,Pigs,Suidae,Warthogs,Wart Hogs,Hog, Wart,Hogs, Wart,Wart Hog
D013570 Synaptic Membranes Cell membranes associated with synapses. Both presynaptic and postsynaptic membranes are included along with their integral or tightly associated specializations for the release or reception of transmitters. Membrane, Synaptic,Membranes, Synaptic,Synaptic Membrane
D018079 Receptors, GABA Cell-surface proteins that bind GAMMA-AMINOBUTYRIC ACID with high affinity and trigger changes that influence the behavior of cells. GABA-A receptors control chloride channels formed by the receptor complex itself. They are blocked by bicuculline and usually have modulatory sites sensitive to benzodiazepines and barbiturates. GABA-B receptors act through G-proteins on several effector systems, are insensitive to bicuculline, and have a high affinity for L-baclofen. GABA Receptors,Receptors, gamma-Aminobutyric Acid,gamma-Aminobutyric Acid Receptors,GABA Receptor,gamma-Aminobutyric Acid Receptor,Receptor, GABA,Receptor, gamma-Aminobutyric Acid,Receptors, gamma Aminobutyric Acid,gamma Aminobutyric Acid Receptor,gamma Aminobutyric Acid Receptors
D018756 GABA Antagonists Drugs that bind to but do not activate GABA RECEPTORS, thereby blocking the actions of endogenous GAMMA-AMINOBUTYRIC ACID and GABA RECEPTOR AGONISTS. gamma-Aminobutyric Acid Antagonists,GABA Antagonist,GABA Receptor Antagonists,Acid Antagonists, gamma-Aminobutyric,Antagonist, GABA,Antagonists, GABA,Antagonists, GABA Receptor,Antagonists, gamma-Aminobutyric Acid,Receptor Antagonists, GABA,gamma Aminobutyric Acid Antagonists

Related Publications

M Facklam, and N G Bowery
January 1983, British journal of pharmacology,
M Facklam, and N G Bowery
January 1990, Neurochemistry international,
M Facklam, and N G Bowery
February 1997, British journal of pharmacology,
M Facklam, and N G Bowery
January 1990, Ukrainskii biokhimicheskii zhurnal (1978),
M Facklam, and N G Bowery
January 1999, Methods in molecular biology (Clifton, N.J.),
M Facklam, and N G Bowery
January 1980, Advances in biochemical psychopharmacology,
M Facklam, and N G Bowery
September 1982, The Journal of pharmacology and experimental therapeutics,
M Facklam, and N G Bowery
October 1990, Biochemical and biophysical research communications,
M Facklam, and N G Bowery
November 1977, Biochemical pharmacology,
Copied contents to your clipboard!